KRAS G12D：如何从直接抑制走向靶向降解
KRAS G12D是胰腺癌、结直肠癌和肺癌等实体瘤中的重要驱动突变。MRTX1133等分子的出现证明了KRAS G12D可以被直接药理干预，而PROTAC等靶向蛋白降解技术进一步将作用模式从“占据并抑制KRAS”推进到“募集E3连接酶并清除KRAS蛋白”。
主题
KRAS G12D
用于检测、定量和定位抗原与抗体的技术——ELISA、免疫印迹、免疫组化与流式细胞术。以下是我们知识库中标注该主题的实验方案、常见问题与技术文章。
4 项资源 · 实验方案、常见问题与文章
KRAS G12D: How Direct Inhibition Is Advancing Toward Targeted Degradation
KRAS G12D is an important driver mutation in solid tumors such as pancreatic, colorectal, and lung cancers. The emergence of molecules such as MRTX1133 has demonstrated that KRAS G12D can be directly targeted pharmacologically, whereas targeted protein degradation technologies such as PROTACs ...
2025 KRAS Targeted Drug Progress
In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
2025 KRAS靶向药物进展
在癌症研究领域，KRAS基因一直占据着重要且特殊的地位。多年来，由于其复杂的结构和功能特性，KRAS被视为 “不可成药” 靶点，然而随着科研技术的不断进步，针对KRAS的靶向治疗取得了突破性进展。
相关主题
常与免疫学实验一起研究的技术。
危险品化学品经营许可证（带存储）